Private Equity
Amuso, a UK-based operator of online trivia contests for cash prizes, has raised $1.5 million in new VC funding. Return backer Mangrove Capital Partners was joined by undisclosed angel investors.
3 min read · 14 October 2009
Omega Funds, a direct secondaries firm focused on the healthcare sector, has completed three transactions, totaling 25 companies at an original sellers' cost of more than $125 million. The only identified seller was Lombard Odier, which sold stakes in nine portfolio companies.
2 min read · 13 October 2009
GroundWork Open Source Inc., a San Francisco-based provider of open-source systems and network management software, has raised $5 million in Series D funding. Canaan Partners led the round, and was joined by fellow return backers Jafco Ventures, Mayfield Fund and SAP Ventures.
4 min read · 13 October 2009
2 min read · 13 October 2009
5 min read · 13 October 2009
Ariana Pharma, a drug discovery and development services business, will receive EUR 1 million ($1.5 million) from France's innovation agency, OSEO, as part of the IMAkinib program. IMAkinib is a collaborative program to develop biomarkers for oncology.
3 min read · 13 October 2009
PharmaDiagnostics NV, a Brussels-based developer of screening technology has raised EUR 2.5 million ($3.7 million) in a second round of funding from Capital-E and an undisclosed group of investors.
3 min read · 13 October 2009
Deezer, a Paris-based digital music company, has raised €6.5 million in new VC funding. Backers include AGF Private Equity and CM-CIC Capital Prive.
2 min read · 12 October 2009
Heptares Therapeutics Ltd., a UK-based developer of drugs targeting G-protein-coupled receptors, has signed a strategic agreement with Novartis Option Fund, whereby it will generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis. The deal includes up to $200 million in upfront and milestone payments, plus potential royalties. Earlier this year, Heptares raised £21 million in Series A funding from Novartis, Clarus Ventures and MVM Life Science Partners.
3 min read · 12 October 2009
Crescendo Biologics, a UK-based developer of fragment antibody technology platforms, has raised £4.5 million in seed funding. Sofinnova Partners led the round, and was joined by Aitua, Avlar BioVentures and the Rainbow Seed Fund.
4 min read · 12 October 2009
